2021


Ascentage Pharma’s MDM2-p53 Inhibitor APG-115 Granted Fast Track Designation by the US FDA for the Treatment of Relapsed/Refractory Unresectable or Metastatic Melanoma

(pdf,441KB)


Poll Results of the Extraordinary General Meeting Held on September 20,2021

(pdf,438KB)


(1) Disclosable Transactions — Subscription of Commercial Paper and Structured Financial Products and (2) Supplemental Announcement in relation to the 2021 Interim Report

(pdf,114KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August

(pdf,63KB)


Form of Proxy for the Extraordinary General Meeting to be Held on September 20, 2021

(pdf,589KB)


Notice Of Extraordinary General Meeting

(pdf,82KB)


Circular (1) Connected Transaction — Proposed Grant of RSUs to Connected Selected Persons;(2) Proposed Grant of RSU Specific Mandate to Issue Shares under the 2021 RSU scheme; (3) Proposed Grant of Warrant Specific Mandate to Issue Unlisted Warrants and Warrant Shares and (4) Notice of Extraordinary General Meeting

(pdf,1MB)


Retirement of Chief Operating Officer

(pdf,61KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July(Revised)

(pdf,64KB)


Announcement of Unaudited Interim Results for the Six Months Ended JUNE 30, 2021

(pdf,437KB)


Notice of Board Meeting

(pdf,57KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July

(pdf,984KB)


Delay in Despatch of Circular in relation to (1) Proposed Issuance of Unlisted Warrants under Specific Mandate; and (2) Connected Trsansactions — Proposed Grant of Awards under the 2021 RSU Scheme to Independent Non-executive Directors and Chief Commercial Officer

(pdf,433KB)


Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325

(pdf,440KB)


Connected Transaction Cancellation of Proposed Grant of Awards and Proposed Re-grant of Awards under the 2021 RSU Scheme to independent non-executive Directors

(pdf,446KB)


Next Day Disclosure Return

(pdf,32KB)


Ascentage Pharma’s MDM2-p53 Inhibitor, APG-115 (Alrizomadlin), Received an Orphan Drug Designation by the FDA for the Treatment of Stage IIB-IV Melanoma

(pdf,446KB)


Ascentage Pharma Establishes Cooperation with the US National Cancer Institute to advance the Clinical Development of Ascentage Pharma’s Bcl-2/Bcl-xL inhibitor APG-1252

(pdf,441KB)


Inside Information – Entry Into of the HQP1351 Collaboration and License agreement and the APG2575 Combination Therapy Strategic Collaboration and Clinical Trial Agreement; Issuance of New Shares under General Mandate; and Proposed Issuance of Unlisted Warrants under Specific Mandate

(pdf,159KB)


Connected Transaction Proposed Grant of Awards under the 2021 RSU Scheme to Independent Non-executive Directors Appointment of Independent Financial Adviser

(pdf,446KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June

(pdf,278KB)


Next Day Disclosure Return

(pdf,169KB)


2020 Environmental, Social and Governance Report

(pdf,5MB)


CLARIFICATION ANNOUNCEMENT GRANT OF AWARDS UNDER THE 2021 RSU SCHEME TO THE INDEPENDENT SELECTED PERSONS

(pdf,433KB)


UPDATE ANNOUNCEMENT GRANT OF AWARDS UNDER THE 2021 RSU SCHEME

(pdf,436KB)


Ascentage Pharma Announces IND Clearance by the US FDA for APG2575 as Single Agent or in Combinations for the Treatment of ER+ Breast Cancer and Other Solid Tumors

(pdf,74KB)


Ascentage Pharma Delivers Oral Presentation Featuring Updated Data Demonstrating Promising Efficacy and
Safety of APG-2575 in Patients with Relapsed or Refractory CLL/SLL; APG-115 Demonstrating Complete Response in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant or Refractory to Prior Immuno-Oncologic Drugs

Download (pdf,459KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2021

Download (pdf,590KB)


SUPPLEMENTAL ANNOUNCEMENT GRANT OF AWARDS UNDER THE 2021 RSU SCHEME AND CONNECTED TRANSACTION PROPOSED GRANT OF AWARDS UNDER THE 2021 RSU SCHEME TO CHIEF COMMERCIAL OFFICER AND INDEPENDENT NON-EXECUTIVE DIRECTOR

Download (pdf,446KB)


GRANT OF AWARDS UNDER THE 2021 RSU SCHEME AND CONNECTED TRANSACTION PROPOSED GRANT OF AWARDS UNDER THE 2021 RSU SCHEME TO CHIEF COMMERCIAL OFFICER

Download (pdf,84KB)


Ascentage Pharma to Announce Updated Data of Bcl-2 Inhibitor Lisaftoclax (APG-2575) Demonstrating an Objective Response Rate of Around 80% and Therapeutic Potential in Patients with R/R CLL/SLL in
Oral Presentation at the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO)

Download (pdf,459KB)


POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 10, 2021

Download (pdf,81KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2021

Download (pdf,546 KB)


Ascentage Pharma to Announce Results from Four Clinical Studies at 2021 ASCO Annual Meeting, with Data of Two of Its Drug Candidates Including Lisaftoclax (APG-2575) to Be Released in Oral Presentations for the First Time

Download (pdf,78 KB)


Presentation by Ascentage Pharma of Results of Latest Preclinical Studies at 2021 American Association for Cancer Research (AACR) Annual Meeting which Demonstrate Potential of Multiple Combination Therapies

Download (pdf,462 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2021

Download (pdf,546 KB)


CLARIFICATION ANNOUNCEMENT IN RELATION TO RESIGNATION OF NON-EXECUTIVE DIRECTOR AND
APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

Download (pdf,436 KB)


ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2020

Download (pdf,425 KB)


List of directors and their roles and functions

Download (pdf,433 KB)


RESIGNATION OF NON-EXECUTIVE DIRECTOR AND APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR RESIGNATION OF NON-EXECUTIVE DIRECTOR

Download (pdf,442 KB)


Ascentage Pharma’s First Third-Generation BCR-ABL Inhibitor in China Olverembatinib (HQP1351) Recommended for Breakthrough Therapy Designation

Download (pdf,455 KB)


NOTICE OF BOARD MEETING

Download (pdf,432 KB)


CLARIFICATION ANNOUNCEMENT IN RELATION TO GRANT OF AWARDS UNDER THE RSU SCHEME

Download (pdf,436 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2021

Download (pdf,550 KB)


Next Day Disclosure Return

Download (pdf,46 KB)


CLOSING OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

Download (pdf,111 KB)


PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

Download (pdf,181 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2021

Download (pdf,532 KB)


Adoption of the 2021 RSU scheme

Download (pdf,88 KB)


Voluntary Announcement -APG-2575 Granted the Fifth Orphan Drug Designation by the US FDA

Download (pdf,438 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2020

(pdf,545 KB)


Voluntary Announcement -Ascentage Pharma Obtained its 9th Orphan Drug Designation from the US FDA in 2020, Setting a Record among Chinese Biopharmaceutical Companies

Download (pdf,448 KB)

2020


Voluntary Announcement -Received Milestone Payment for the Partnership with UNITY Biotechnology

Download (pdf,436 KB)


Voluntary Announcement -Announcement of Updates on the Clinical Development of APG-2575, Including An Objective Response Rate of 70% in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Download (pdf,74 KB)


Voluntary Announcement -Positive Data from Pivotal Phase II Studies of HQP1351 (Olverembatinib) was Announced at 2020 American Society of Hematology Annual Meeting

Download (pdf,437 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2020

(pdf,152 KB)


Voluntary Announcement -Phase IIa Clinical Study of APG-115 as Single Agent or in Combination with APG-2575 Receives Clearances in China and the U.S.

Download (pdf,438 KB)


Clarification Announcement

Download (pdf,432 KB)


Voluntary Announcement -Entry into of an Agreement with the University of Michigan to Obtain An Exclusive License for a MDM2 Protein Degrader Using PROTACs Technology

Download (pdf,184 KB)


Next Day Disclosure Return

Download (pdf,39 KB)


Voluntary Announcement -APG-2575 Completed Dosing of the First Patient in Europe in Phase Ib/II Clinical Study

Download (pdf,64 KB)


Voluntary Announcement -APG-2575 Receives Approvals for Two Phase Ib/II Clinical Studies in China

Download (pdf,205 KB)


Voluntary Announcement -Ascentage Pharma Accepted for the Third Time to Release Updated Clinical Data of HQP1351 (Olverembatinib) in Drug-Resistant Chronic Myeloid Leukemia in an Oral Presentation at the American Society of Hematology Annual Meeting

Download (pdf,66 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2020

Download (pdf,533 KB)


Voluntary Announcement -APG-115 Granted Approval for the Phase Ib/II Clinical Study in China

Download (pdf,68 KB)


Voluntary Announcement -Olverembatinib (HQP1351) of Ascentage Pharma is Included in the List of “Priority Review

Download (pdf,69 KB)


Voluntary Announcement -APG-115 and APG-1252 Granted Orphan Drug Designation by the US FDA

Download (pdf,434 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2020

Download (pdf,538 KB)


Grant of Awards under the RSU Scheme

Download (pdf,435 KB)


Voluntary Announcement -APG-115 Granted Orphan Drug Designation by the FDA for the Treatment of Gastric Cancer

Download (pdf,436 KB)


2020 Interim Report

Download (pdf,1 MB)


Voluntary Announcement -APG-2575 Granted Second Orphan Drug Designation by the US FDA

Download (pdf,436 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2020

Download (pdf,642 KB)


Announcement of Unaudited Interim Results for the Six Months Ended June 30,2020

Download (pdf,266 KB)


Voluntary Announcement -Becoming A Constituent of the Hang Seng Family of Indexes

Download (pdf,65 KB)


Notice of Board Meeting

Download (pdf,61 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2020

Download (pdf,601 KB)


Voluntary Announcement – APG-115 Completed Dosing of the First Patient in Phase Ib Clinical Study in China

Download (pdf,63 KB)


Voluntary Announcement – APG-2575 Granted Orphan Drug Designation by the US FDA

Download (pdf,70 KB)


Next Day Disclosure Return

Download (pdf,253 KB)


Closing of Placing of New Shares under General Mandate

Download (pdf,476 KB)


2019 Environmental, Social and Governance Report

Download (pdf,3 MB)


Placing of New Shares under General Mandate

Download (pdf,167 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2020

Download (pdf,601 KB)


Voluntary Announcement – Clinical Collaboration with MSD

Download (pdf,69 KB)


Voluntary Announcement – Clinical Collaboration with Acerta Pharma, the Hematology Research and Development Center of Excellence of AstraZeneca

Download (pdf,70 KB)


Poll Results of the Annual General Meeting Held on June 19, 2020

Download (pdf,83 KB)


Voluntary Announcement – Submission of New Drug Application for HQP1351 in China

Download (pdf,69 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2020

Download (pdf,602 KB)


Voluntary Announcement – Latest Clinical Data of Apoptosis Targeting Drug Candidates was Presented at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting

Download (pdf,445 KB)


Voluntary Announcement – HQP1351 Granted Fast Track Designation by the US FDA

Download (pdf,70.5 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2020

Download (pdf,634 KB)


Voluntary Announcement – HQP1351 Granted Orphan Drug Designation by the U.S. FDA

Download (pdf,451KB)


Form of Proxy for the Annual General Meeting to Be Held on June 19, 2020

Download (pdf,218KB)


Notice of Annual General Meeting

Download (pdf,93KB)


2019 Annual Report

Download (pdf,1.78MB)


Proposed Re-election of Retiring Directors and Proposed Granting of General Mandates to Issue Shares and Repurchase Shares and Notice of Annual General Meeting

Download (pdf,235KB)


Voluntary Announcement – Approval for the Phase Ib/II Clinical Study of APG-2575 in China

Download (pdf,86 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2020

Download (pdf,459 KB)


Announcement of Annual Results for the Year Ended December 31, 2019

Download (pdf,315 KB)


Voluntary Announcement – APG-2575 completed dosing of first patient in Phase Ib/II trial in the U.S.

Download (pdf,467 KB)


Notice of Board Meeting

Download (pdf,127 KB)


Voluntary Announcement – Approvals obtained in China and U.S. for three phase Ib/II clinical trials of APG-2575

Download (pdf,468 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2020

Download (pdf,627 KB)


Voluntary Announcement – Approval of phase Ib/II clinical trial of APG-1387 for the treatment of advanced pancreatic cancer in combination with chemotherapy in China

Download (pdf,111 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2020

Download (pdf,343 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2019


 

 

Voluntary Announcenment – Studies of HQP1351 nominated the “Best of ASH” at the 2019 American Society of Hematology Annual Meeting

Download (pdf,128 KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2019

Download (pdf,441 KB)

Next Day Disclosure Return

Download (pdf,259 KB)

FULL EXERCISE OF THE OVER-ALLOTMENT OPTION,STABILISING ACTIONS AND END OF STABILISATION PERIOD

Download (pdf,138 KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2019

Download (pdf,1015 KB)

Amended and Restated Memorandum and Articles of Association

Download (pdf,418 KB)

Terms of Reference for Nomination Committee

Download (pdf,145 KB)

Terms of Reference for Audit Committee

Download (pdf,143 KB)

Terms of Reference for Remuneration Committee

Download (pdf,148 KB)

List of Directors and their Roles and Functions

Download (pdf,123 KB)

Procedures for election as director

Download (pdf,122 KB)

Board Diversity policy

Download (pdf,121 KB)

Shareholders Communication Policy

Download (pdf,129 KB)

Global Offering – Allotment Results

Download (pdf,1505 KB)